Skip to content

house · Committee report

H. Rept. 118-958

AMERICAN MEDICAL INNOVATION AND INVESTMENT ACT OF 2024

2024-12-27

Committees

Associated legislation

Text

Background

H.R. 8816 was introduced on June 25, 2024, and was referred to the Committee on Energy and Commerce and the Committee on Ways and Means. Committee Hearings The Committee on Ways and Means held the following hearing concerning the policy in H.R. 8816: On May 10, 2023, the Committee on Ways and Means Health Subcommittee held a hearing titled, ``Examining Policies that Inhibit Innovation and Patient Access'' to probe policies limiting the number of innovative treatments and cures that reach patients. The hearing explored opportunities to improve the Medicare benefit through more transparent coverage decisions, improved Alzheimer's treatment, and other ways to improve the Medicare benefit.

Committee Action

The Committee on Ways and Means marked up H.R. 8816, the American Medical Innovation and Investment Act of 2024, on June 27, 2024, and favorably reported the bill, as amended, to the House of Representatives (with quorum being present). D. Designated Hearing Pursuant to clause 3(c)(6) of rule XIII, the following hearing was used to develop and consider H.R. 8816: ``Hearing on Examining Policies that Inhibit Innovation and Patient Access'' May 10, 2023. II. EXPLANATION OF THE BILL A. Reasons for Change This legislation encompasses several policies intended to improve the Medicare benefit. Cognitive testing as included in the Medicare Annual Wellness Visit does not require specific tools to be used, meaning testing can fluctuate in effectiveness. National Coverage Determinations with Coverage with Evidence Development protocols are frequently endless coverage restrictions instead of meaningful coverage processes to collect evidence, undermining the true intent of the program. Full National Coverage Determinations can be confusing and opaque for applicants, with applicants not knowing whether or not the application is complete or if they are incomplete how they did not meet the standards required for consideration. Local Coverage Determinations can exceed federal law or payment policy in contradiction to the federal code. External infusion pumps and non-self-administrable home infusion drugs are more convenient for patients, but Medicare guidance has not allowed their reimbursement. Medicare coverage policies for artificial intelligence powered dosing devices is unclear. Medicare coverage policies for prescription digital therapeutics is unclear. Medically tailored meals can greatly benefit patient recovery but there is not sufficient data to support full programmatic changes. B. Explanation of Provisions Section 1. Short title The short title is ``American Medical Innovation and Investment Act of 2024''. Section 2. Cognitive Impairment Detection Benefit in the Medicare Annual Wellness Visit and Initial Preventive Physical Examination This provision would require the cognitive impairment test in the Medicare Annual Wellness Visit to be performed using a cognitive impairment detection tool identified by the National Institute on Aging. Section 3. Improving the National and Local Coverage Determination Process Under the Medicare Program This provision would require National Coverage Determinations (NCDs) with Coverage with Evidence Development (CEDs) to be reconsidered every 10 years unless it is necessary for the collection of additional evidence; require Medicare to notify NCD applicants whether the application is complete or not within 90 days; and prevent Local Coverage Determinations (LCDs) from superseding federal law, ruling, regulation, NCD, payment policy, or coding policy. Section 4. Medicare Coverage of External Infusion Pumps and Non-Self- Administrable Home Infusion Drugs This provision would guarantee coverage of self- administered home infusion pumps under Medicare by clarifying the definition of external infusion pumps as ``appropriate for use in the home'' for certain individuals and educate members on any cost sharing differential. Section 5. Guidance on Medicare Payment for Certain Items Involving Artificial Intelligence This provision would require Medicare to clarify and update coverage for AI-enabled dosing devices. Section 6. Clarifying Payment for Prescription Digital Therapeutics Under Medicare This provision would require Medicare to clarify and update coverage for Prescription Digital Therapeutics. Section 7. Medically Tailored Home-Delivered Meals Demonstration Program This provision would require Medicare to stand up a demonstration program for medically tailored home-delivered meals in a budget neutral manner to help seniors improve health outcomes and reduce readmission rates. C. Effective Date Sec. 2 of the bill would become effective January 1, 2025. Sec. 3 of the bill would become effective upon enactment of the bill. Sec. 4 of the bill would become effective upon enactment of the bill. Sec. 5 of the bill would become effective January 1, 2026. Sec. 6 of the bill would become effective January 1, 2026. Sec. 7 of the bill would become effective January 1, 2025. III. VOTES OF THE COMMITTEE In compliance with the Rules of the House of Representatives, the following statement is made concerning the vote of the Committee on Ways and Means during the markup consideration of H.R. 8816, the ``American Medical Innovation and Investment Act,'' on June 27, 2024. H.R. 8816 was ordered favorably reported to the House of Representatives as amended by a roll call vote of 40 yeas to 0 nays (with a quorum being present). The vote was as follows: ---------------------------------------------------------------------------------------------------------------- Representative Yea Nay Present Representative Yea Nay Present ---------------------------------------------------------------------------------------------------------------- Mr. Smith (MO)..................... X ...... ......... Mr. Neal............. X ...... ......... Mr. Buchanan....................... X ...... ......... Mr. Doggett.......... X ...... ......... Mr. Smith (NE)..................... X ...... ......... Mr. Thompson......... X ...... ......... Mr. Kelly.......................... X ...... ......... Mr. Larson........... X ...... ......... Mr. Schweikert..................... X ...... ......... Mr. Blumenauer....... X ...... ......... Mr. LaHood......................... X ...... ......... Mr. Pascrell......... X ...... ......... Dr. Wenstrup....................... X ...... ......... Mr. Davis............ X ...... ......... Mr. Arrington...................... X ...... ......... Ms. Sanchez.......... X ...... ......... Dr. Ferguson....................... X ...... ......... Ms. Sewell........... X ...... ......... Mr. Estes.......................... ...... ...... ......... Ms. DelBene.......... X ...... ......... Mr. Smucker........................ X ...... ......... Ms. Chu.............. X ...... ......... Mr. Hern........................... X ...... ......... Ms. Moore............ X ...... ......... Ms. Miller......................... X ...... ......... Mr. Kildee........... X ...... ......... Dr. Murphy......................... ...... ...... ......... Mr. Beyer............ X ...... ......... Mr. Kustoff........................ X ...... ......... Mr. Evans............ ...... ...... ......... Mr. Fitzpatrick.................... X ...... ......... Mr. Schneider........ X ...... ......... Mr. Steube......................... X ...... ......... Mr. Panetta.......... X ...... ......... Ms. Tenney......................... X ...... ......... Mr. Gomez............ X ...... ......... Mrs. Fischbach..................... X ...... ......... Mr. Moore.......................... X ...... ......... Mrs. Steel......................... X ...... ......... Ms. Van Duyne...................... X ...... ......... Mr. Feenstra....................... X ...... ......... Ms. Malliotakis.................... X ...... ......... Mr. Carey.......................... X ...... ......... ---------------------------------------------------------------------------------------------------------------- IV. BUDGET EFFECTS OF THE BILL A. Committee Estimate of Budgetary Effects In compliance with clause 3(d) of rule XIII of the Rules of the House of Representatives, the following statement is made concerning the effects on the budget of the bill, H.R. 8816, as reported. The estimate prepared by the Congressional Budget Office (CBO) is included below. B. Statement Regarding New Budget Authority and Tax Expenditures Budget Authority In compliance with clause 3(c)(2) of rule XIII of the Rules of the House of Representatives, the Committee states that the bill involved no new or increased budget authority. The Committee states further that the bill involves no new or increased tax expenditures. C. Cost Estimate Prepared by the Congressional Budget Office In compliance with clause 3(c)(3) of rule XIII of the Rules of the House of Representatives, requiring a cost estimate prepared by the CBO, the following statement by CBO is provided. [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Summary of legislation: The House Committee on Ways and Means marked up a total of 10 bills on May 8, 2024, and on June 27, 2024. This document provides estimates for six of those bills. Generally, the bills would: Modify Medicare's payment policy with respect to ambulances and hospitals that operate in rural areas, Provide Medicare-funded graduate medical education slots at rural hospitals, Reinstate nursing certification programs at facilities that had previously lost the ability to operate those programs, Establish a Medicare pilot program to award grants to rural hospitals, Revise the definition of ``rural emergency hospital'' under Medicare, and Expand Medicare coverage for the home infusion of drugs. Estimated Federal cost: Three of the bills would affect direct spending; the estimated effects are shown in Table 1. The costs fall within budget function 570 (Medicare). TABLE 1.--ESTIMATED EFFECTS ON DIRECT SPENDING OF MEDICARE LEGISLATION, AS ORDERED REPORTED BY THE HOUSE COMMITTEE ON WAYS AND MEANS ON MAY 8, 2024, AND JUNE 27, 2024 -------------------------------------------------------------------------------------------------------------------------------------------------------- By fiscal year, millions of dollars-- --------------------------------------------------------------------------------------------------- 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2025-2029 2025-2034 -------------------------------------------------------------------------------------------------------------------------------------------------------- INCREASES OR DECREASES (-) IN DIRECT SPENDING H.R. 7931: Budget Authority................................ 1 3 4 5 6 8 9 11 13 14 19 74 Estimated Outlays............................... 1 3 5 5 6 8 9 11 13 14 19 74 H.R. 8246: Budget Authority................................ 0 29 117 193 284 336 443 551 651 807 623 3,411 Estimated Outlays............................... 0 29 117 193 284 336 443 551 651 807 623 3,411 H.R. 8816: Budget Authority................................ 1 -8 -11 -14 -13 -15 -17 -17 -18 -17 -45 -129 Estimated Outlays............................... 1 -8 -11 -14 -12 -15 -17 -18 -18 -17 -45 -129 -------------------------------------------------------------------------------------------------------------------------------------------------------- Components may not sum to totals because of rounding. Basis of estimate: For this estimate, CBO assumes that each bill will be enacted in fiscal year 2025. Direct spending: CBO estimates that enacting H.R. 8235, H.R. 8244, and H.R. 8245 would have no effect on direct spending. CBO estimates that enacting the other three of the six bills would affect direct spending. H.R. 7931, the Preserving Emergency Access in Key Sites Act, would increase Medicare payments for certain rural ambulance suppliers and hospitals. Payments would rise to 101 percent of what is termed reasonable cost, which is greater than amounts under current law. CBO estimates that enacting the bill would increase direct spending by $74 million over the 2025-2034 period and that enacting the bill would not affect revenues. H.R. 8246, the Second Chances for Rural Hospitals Act, would allow critical access hospitals and certain small rural hospitals that closed between January 1, 2014, and December 26, 2020, to reopen as rural emergency hospitals. Those facilities would qualify for additional Medicare payments, including higher reimbursement rates and annual facility payments, depending on their distance from other hospitals. Based on an assessment of the number of additional locations that would become eligible for monthly payments, CBO estimates that enacting the bill would result in about 6,000 additional monthly payments to rural emergency hospitals, increasing Medicare fee-for-service spending by $2 billion. That change also would increase payments to Medicare Advantage plans. CBO estimates that enacting H.R. 8246 would increase total direct spending by $3.4 billion over the 2025 2034 period and that enacting the bill would not affect revenues. H.R. 8816, the American Medical Innovation and Investment Act of 2024, would modify rules for determining national and local coverage in Medicare's programs and revise certain Medicare payments and benefits. CBO estimates that enacting the bill would decrease net direct spending by $129 million over the 2025-2034 period. The bill would provide $5 million to the Centers for Medicare & Medicaid Services, which CBO estimates would increase direct spending by the same amount over the 2025-2034 period to implement changes to the national and local coverage process. The bill also would expand Medicare coverage for the home infusion of drugs. CBO estimates that enacting that provision would reduce direct spending by $134 million over the 2025-2034 period. The bill also would direct the Department of Health and Human Services to conduct a four-year demonstration project offering medically tailored, home- delivered meals to beneficiaries with heart disease, diabetes, or other conditions. CBO estimates that enacting the medically tailored meals demonstration would not significantly affect direct spending over the 2025-2034 period. CBO estimates that enacting the bill would not affect revenues. Spending subject to appropriation: CBO has not completed estimates of spending subject to appropriation for any of the bills. Pay-As-You-Go considerations: The Statutory Pay-As-You-Go Act of 2010 establishes budget-reporting and enforcement procedures for legislation affecting direct spending or revenues. The net changes in outlays for the three bills that are subject to pay-as-you-go procedures are shown in Table 1. Increase in long-term net direct spending and deficits: CBO estimates that enacting H.R. 8246 would increase net direct spending by more than $2.5 billion in at least one of the four consecutive 10-year periods beginning in 2035. None of the other bills, if enacted, would do so. CBO estimates that enacting H.R. 8246 would increase on- budget deficits by more than $5 billion in at least one of the four consecutive 10-year periods beginning in 2025. None of the other bills, if enacted, would do so. Mandates: The bill contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act. Previous CBO estimate: On March 13, 2024, CBO transmitted a cost estimate for H.R. 5397, the Joe Fiandra Access to Home Infusion Act of 2023, as ordered reported by the House Committee on Energy and Commerce on December 6, 2023. Section 2 of H.R. 5397 is similar to section 4 of H.R. 8816. Both bills would expand Medicare coverage for the home infusion of drugs. Estimate prepared by: Federal Costs: Austin Barselau (Medicare Advantage and Medicare Part D); Cornelia Hall (Medicare Part B); Hudson Osgood (Medicare Part B); Lara Robillard (Medicare Part B); Sarah Sajewski (Medicare Part A); Julia Sheriff (Medicare Part A); Noah Zwiefel (Medicare Advantage and Medicare Part D). Mandates: Andrew Laughlin. Estimate reviewed by: Asha Saavoss, Chief, Health Systems and Medicare Cost Estimates Unit; Kathleen FitzGerald, Chief, Public and Private Mandates Unit; Chad Chirico, Director of Budget Analysis. Estimate approved by: Phillip L. Swagel, Director, Congressional Budget Office. V. OTHER MATTERS TO BE DISCUSSED UNDER THE RULES OF THE HOUSE A. Committee Oversight Findings and Recommendations With respect to clause 3(c)(1) of rule XIII of the Rules of the House of Representatives, the Committee made findings and recommendations that are reflected in this report. B. Statement of General Performance Goals and Objectives With respect to clause 3(c)(4) of rule XIII of the Rules of the House of Representatives, the Committee advises that the bill does not authority funding, so no statement of general performance goals and objectives is required. C. Information Relating to Unfunded Mandates This information is provided in accordance with section 423 of the Unfunded Mandates Reform Act of 1995 (Pub. L. No. 104- 4). The Committee has determined that the bill does not contain Federal mandates on the private sector. The Committee has determined that the bill does not impose a Federal intergovernmental mandate on State, local, or tribal governments. D. Congressional Earmarks, Limited Tax Benefits, and Limited Tariff Benefits With respect to clause 9 of rule XXI of the Rules of the House of Representatives, the Committee has carefully reviewed the provisions of the bill, and states that the provisions of the bill do not contain any congressional earmarks, limited tax benefits, or limited tariff benefits within the meaning of the rule. E. Duplication of Federal Programs In compliance with clause 3(c)(5) of rule XIII of the Rules of the House of Representatives, the Committee states that no provision of the bill establishes or reauthorizes: (1) a program of the Federal Government known to be duplicative of another Federal program; (2) a program included in any report from the Government Accountability Office to Congress pursuant to section 21 of Public Law 111-139; or (3) a program related to a program identified in the most recent Catalog of Federal Domestic Assistance, published pursuant to the Federal Program Information Act (Pub. L. No. 95-220, as amended by Pub. L. No. 98-169). VI. CHANGES IN EXISTING LAW MADE BY THE BILL, AS REPORTED In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as

Source: https://api.congress.gov/v3/committee-report/118/hrpt/958